Corrigendum to ‟Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulationsˮ [Inform. Med. Unlocked 23 (2021) 1-9/100541]

Detalles Bibliográficos
Autores principales: Mahdian, Soodeh, Zarrabi, Mahboobeh, Panahi, Yunes, Dabbagh Sadeghpour, Somayyeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158040/
https://www.ncbi.nlm.nih.gov/pubmed/37362152
http://dx.doi.org/10.1016/j.imu.2023.101263
_version_ 1785036879994814464
author Mahdian, Soodeh
Zarrabi, Mahboobeh
Panahi, Yunes
Dabbagh Sadeghpour, Somayyeh
author_facet Mahdian, Soodeh
Zarrabi, Mahboobeh
Panahi, Yunes
Dabbagh Sadeghpour, Somayyeh
author_sort Mahdian, Soodeh
collection PubMed
description
format Online
Article
Text
id pubmed-10158040
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Author(s). Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-101580402023-05-04 Corrigendum to ‟Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulationsˮ [Inform. Med. Unlocked 23 (2021) 1-9/100541] Mahdian, Soodeh Zarrabi, Mahboobeh Panahi, Yunes Dabbagh Sadeghpour, Somayyeh Inform Med Unlocked Article The Author(s). Published by Elsevier Ltd. 2023-05-04 /pmc/articles/PMC10158040/ /pubmed/37362152 http://dx.doi.org/10.1016/j.imu.2023.101263 Text en © 2023 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Mahdian, Soodeh
Zarrabi, Mahboobeh
Panahi, Yunes
Dabbagh Sadeghpour, Somayyeh
Corrigendum to ‟Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulationsˮ [Inform. Med. Unlocked 23 (2021) 1-9/100541]
title Corrigendum to ‟Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulationsˮ [Inform. Med. Unlocked 23 (2021) 1-9/100541]
title_full Corrigendum to ‟Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulationsˮ [Inform. Med. Unlocked 23 (2021) 1-9/100541]
title_fullStr Corrigendum to ‟Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulationsˮ [Inform. Med. Unlocked 23 (2021) 1-9/100541]
title_full_unstemmed Corrigendum to ‟Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulationsˮ [Inform. Med. Unlocked 23 (2021) 1-9/100541]
title_short Corrigendum to ‟Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulationsˮ [Inform. Med. Unlocked 23 (2021) 1-9/100541]
title_sort corrigendum to ‟repurposing fda-approved drugs to fight covid-19 using in silico methods: targeting sars-cov-2 rdrp enzyme and host cell receptors (ace2, cd147) through virtual screening and molecular dynamic simulationsˮ [inform. med. unlocked 23 (2021) 1-9/100541]
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158040/
https://www.ncbi.nlm.nih.gov/pubmed/37362152
http://dx.doi.org/10.1016/j.imu.2023.101263
work_keys_str_mv AT mahdiansoodeh corrigendumtorepurposingfdaapproveddrugstofightcovid19usinginsilicomethodstargetingsarscov2rdrpenzymeandhostcellreceptorsace2cd147throughvirtualscreeningandmoleculardynamicsimulationsˮinformmedunlocked23202119100541
AT zarrabimahboobeh corrigendumtorepurposingfdaapproveddrugstofightcovid19usinginsilicomethodstargetingsarscov2rdrpenzymeandhostcellreceptorsace2cd147throughvirtualscreeningandmoleculardynamicsimulationsˮinformmedunlocked23202119100541
AT panahiyunes corrigendumtorepurposingfdaapproveddrugstofightcovid19usinginsilicomethodstargetingsarscov2rdrpenzymeandhostcellreceptorsace2cd147throughvirtualscreeningandmoleculardynamicsimulationsˮinformmedunlocked23202119100541
AT dabbaghsadeghpoursomayyeh corrigendumtorepurposingfdaapproveddrugstofightcovid19usinginsilicomethodstargetingsarscov2rdrpenzymeandhostcellreceptorsace2cd147throughvirtualscreeningandmoleculardynamicsimulationsˮinformmedunlocked23202119100541

Ejemplares similares